follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Alitair Pharmaceuticals, Edmond Pharma announce licensing agreement

By

Back to Top Comments Email Print

Latest News

advertisement

Morristown-based Alitair Pharmaceuticals announced Wednesday its licensing agreement with Italian company Edmond Pharma regarding the latter's mucolytic erdosteine. Financial terms of the agreement were not disclosed.

According to the announcement, erdosteine is a mucolytic with antibacterial, anti-inflammatory and antioxidant properties. The agreement allows for Alitair's development of erdosteine as an orphan drug in the United States and Canada.

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top